… ProQR Announces Third Quarter 2022 Operating and FinancialResults Development of Axiomer ® RNA base editing technology … of transformative RNA therapies, today reported its financial and operating results for the third quarter ended …
… ProQR Announces Second Quarter 2022 Operating and FinancialResults ProQR is accelerating the development of its Axiomer … of transformative RNA therapies, today reported its financial and operating results for the second quarter ended …
… ProQR Announces First Quarter 2022 Operating and FinancialResults Post-hoc analyses from Illuminate trial of sepofarsen … of transformative RNA therapies, today reported its financial and operating results for the first quarter ended …
… ProQR Announces Third Quarter 2020 Operating and FinancialResults Illuminate Phase 2/3 trial of sepofarsen expected to … for inherited retinal diseases (IRDs), today reported its financial and operating results for the third quarter ended …
… Announces Fourth Quarter and Full Year 2020 Operating and FinancialResults Phase 2/3 pivotal Illuminate trial of sepofarsen for … for inherited retinal diseases (IRDs), today reported its financial and operating results for the fourth quarter and …
Initial pipeline programs with liver delivery to address Cholestatic Diseases targeting NTCP and Cardiovascular Disease targeting B4GALT1
Development of Axiomer® RNA base editing technology platform continues across multiple therapeutic areas
Streng
Divestment of sepofarsen and ultevursen ophthalmic programs supports ProQR’s strategic focus on Axiomer® RNA editing platform technology and continued advancement of pipeline
€129 M cash and cash equivalents as of June 30, 2023 providing runway into mid-2026
… ProQR Announces Second Quarter 2021 Operating and FinancialResults Top-line data from Phase 2/3 pivotal Illuminate … RNA therapies for genetic eye diseases, today reported its financial and operating results for the second quarter ended …
… ProQR Announces First Quarter 2021 Operating and FinancialResults Phase 2/3 pivotal Illuminate trial of sepofarsen … RNA therapies for genetic eye diseases, today reported its financial and operating results for the first quarter ended …
… ProQR Announces Third Quarter 2021 Operating and FinancialResults Top-line data from pivotal Phase 2/3 Illuminate … Axiomer ® RNA base-editing platform and strengthens financial position with $50 million in upfront and equity and …